{
  "docId": "019de075-7a24-71be-ac51-dd13871aea0a",
  "docSlug": "fd7a76edfe86a80da6108d342915286a",
  "documentTitle": "BioAtla | Investor Presentation Deck | 43 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 43,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 25,
  "notes": "The slide uses a waterfall plot for response and a spider plot for longitudinal tumor burden change.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7a24-71be-ac51-dd13871aea0a/11",
  "deckHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a",
  "deckJsonHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a.json",
  "deckAnchorHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Spider plot of change in target lesion from baseline over time for all evaluable patients.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6af80153-30a9-4a37-a82f-b621608f8a8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Waterfall plot of maximum % change from baseline in sum of target lesions for high TmPS patients.",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "256e2f0c-123c-413f-a52e-de57907a3494",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "list",
      "text": "PR was achieved in 4/7 high TmPS patients receiving the clinically-meaningful 1.8 mg/kg dose Q3W and 2Q3W. Antitumor activity correlates with higher levels of AXL tumor membrane expression in sarcoma patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b53a894-65cf-4a30-85dc-33d7f99a231f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "All patients: Multiple cycles of antineoplastic agents received prior to starting treatment with BA3011. AXL Tumor membrane Percent Score or TmPS = % Score ≥1+; $Tissue biopsy from resection, over 1 year old prior to trial entry. NED = No evidence of disease; 2Synovial sarcoma patient delayed treatment due to unrelated SAE led to progression.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb3c20ca-7cae-4ed1-b7f6-8acd323db16c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Encouraging Phase 1 results with Mecbotamab Vedotin (BA3011) in refractory sarcoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e843780-0d6c-41d6-b42c-4668c1095c92",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "85a559a9-5fa6-490e-b2f5-7bf78fb4bb9b",
      "evidence": "Waterfall plot of maximum % change from baseline in sum of target lesions for high TmPS patients.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 10,
      "beatId": "133082c7-85f5-4973-804e-0345a7f317eb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The deck provides market sizing data for various tumor types",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    },
    {
      "to": 19,
      "from": 11,
      "beatId": "3af527af-8544-4e9d-a8c7-da1d6326498b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents encouraging clinical results and traction in multiple tumor types",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 40,
      "from": 8,
      "beatId": "e2a4fdc0-9030-4acb-8ef9-b3ca594561cc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The deck outlines a clear roadmap for BioAtla's pipeline and milestones",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "2e84312e-7551-4fe1-b34e-202074eadb7a",
      "evidence": "The deck presents market sizing data for various tumor types",
      "position": 1,
      "objective": "What are the potential market opportunities for CAB technology?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}